| Budget Amount *help |
¥44,590,000 (Direct Cost: ¥34,300,000、Indirect Cost: ¥10,290,000)
Fiscal Year 2015: ¥13,390,000 (Direct Cost: ¥10,300,000、Indirect Cost: ¥3,090,000)
Fiscal Year 2014: ¥13,390,000 (Direct Cost: ¥10,300,000、Indirect Cost: ¥3,090,000)
Fiscal Year 2013: ¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
|
|---|
| Outline of Final Research Achievements |
During the study period, more than 100,000 FISH screenings were performed in lung cancer, gynecological cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, and lymphoma. Several fusion genes were identified (unpublished) in gynecological cancer, colon cancer, pancreatic cancer and head and neck cancer and lymphoma.
Genetic abnormalities were comprehensively examined and reported in various lymphomas. Transgenic mice simulating ROS1-positive lung cancer was developed and reported with the results of experiments using ROS1 inhibitors. Novel resistant mechanisms in ALK-positive lung cancer were reported. Clinical trials using corresponding inhibitors were performed for the patients with RET-positive lung cancer or ALK-positive lung cancer, in which I took charge of a central diagnosis. Several recommendations about the diagnosis of ALK-positive lung cancer were made.
|
